We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01477190
First Posted: November 22, 2011
Last Update Posted: November 28, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Gabriele Baldini, Assistant Professor, McGill University Health Center
  Purpose

This is a blinded randomized controlled trial in patients undergoing laparoscopic colon surgery. The aim of this study is to assess whether spinal analgesia with a mixture of bupivacaine and morphine provides better pain relief than systemic morphine in a group of patients undergoing colonic resection and using the Enhanced Recovery After Surgery (ERAS) program.

Twenty patients will receive spinal analgesia and twenty patients will receive only Patient Control Analgesia (PCA).


Condition Intervention Phase
Colon Cancer Inflammatory Bowel Diseases Diverticulitis Drug: Spinal analgesia Drug: Patient Control Analgesia (PCA) Morphine Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program

Resource links provided by NLM:


Further study details as provided by Gabriele Baldini, Assistant Professor, McGill University Health Center:

Primary Outcome Measures:
  • postoperative pain [ Time Frame: daily during hospitalization up to 3 days after the operation ]

Secondary Outcome Measures:
  • opioid consumption [ Time Frame: daily during hospitalization up to 3 days after the operation ]
  • opioid side effects [ Time Frame: daily during hospitalization, participants will be followed for the duration of hospital stay, an expected average of 3 days ]

Enrollment: 40
Study Start Date: October 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Spinal group
Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
Drug: Spinal analgesia
isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
Other Name: Spinal block, intrathecal block
Active Comparator: PCA group
PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Drug: Patient Control Analgesia (PCA) Morphine
PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Other Name: Patient Control Analgesia Morphine.

Detailed Description:
This is a blinded randomized controlled trial in patients undergoing laparoscopic colon surgery. The aim of this study is to assess whether spinal analgesia with a mixture of bupivacaine and morphine provides better pain relief than systemic morphine in a group of patients undergoing colonic resection and using the ERAS program.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients scheduled to undergo laparoscopic colonic resection

Exclusion Criteria:

  • patients who have trouble to understand, read or communicate either in French or in English
  • dementia
  • patients suffering from severe physical disability (arthritis, neuromuscular dysfunction, stroke, paraplegia) or inability to walk or conduct daily activity
  • patients suffering from severe cardiac or respiratory disease (status ASA IV)
  • patients suffering from metastatic carcinoma
  • patients who have a history of chemoradiation within the six months preceding surgery
  • morbid obesity
  • contraindication to spinal analgesia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477190


Locations
Canada, Quebec
Montreal General Hospital
Montreal, Quebec, Canada, H3G1A4
Sponsors and Collaborators
McGill University Health Center
Investigators
Study Director: Franco Carli, Professor McGill University Health Center
  More Information

Responsible Party: Gabriele Baldini, Assistant Professor, Dr, McGill University Health Center
ClinicalTrials.gov Identifier: NCT01477190     History of Changes
Other Study ID Numbers: GEN-06-023(2)
First Submitted: November 16, 2011
First Posted: November 22, 2011
Last Update Posted: November 28, 2011
Last Verified: November 2011

Additional relevant MeSH terms:
Inflammatory Bowel Diseases
Diverticulitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Intraabdominal Infections
Infection
Morphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents